Steve Grun is the Co-Founder and CEO of MNDL Bio, an Israeli startup that uses AI to design better DNA sequences for making proteins—helping companies produce up to 20 times more protein than traditional methods. Their tech takes the guesswork out of gene design for biotech and pharma companies developing new drugs, enzymes, and other biological products. Avraham sat down with Steve to discuss why most biotech companies struggle to produce proteins at scale and how MNDL's AI platform fixes that, how he turned 15 years of academic research into a SaaS product, their $2 million pre-seed raise, tips for tech founders, where he sees the company in five years and much more. Do you have a great innovation? We'd love to hear from you. Contact us by going to https://jmbdavis.com/startup/contact. Learn more at https://jmbdavis.com and https://jmbdavis.com/startup. Also available at https://soundcloud.com/jmbdavis/ mndl-bio. Listen to all of the episodes at https://jmbdavis.com/podcast.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.